Search

Your search keyword '"Kremens, B"' showing total 21 results
Start Over Author "Kremens, B" Database OpenAIRE
21 results on '"Kremens, B"'

1. Metalloenzymes

Author

Pollard, J. W., Danilkovitch-Miagkova, A., Minaguchi, T., Waite, K. A., Buys, T. P. H., Lam, W. L., Müller-Hermelink, H. K., Ott, G., Robb, V. A., Henske, E. P., Lynge, E., Boyd, N., Geisler, C., Seger, R., De Wolf-Peeters, C., Sagaert, X., Sheng, S., Ribatti, D., Verstovsek, S., Akin, C., Stack, M. S., Kitada, S., Gartenhaus, R., Moretti, F., Frühwald, Michael C., Mooi, W. J., Krausz, T., Kefford, R., Peikert, T., Specks, U., Tueting, T., Pföhler, C., Blask, D. E., Stevens, R. G., Nies, A. T., Gotoh, N., Tsuchida, N., Escriba, P., Singh, V., Hickey, M., Saunders, C., Xiao, G.-H., Testa, J. R., Furtwängler, R., Scholler, N., Carbone, M., Furge, K., Woude, G. F. V., Roland, W. C., Muschel, R., Hunter, K., Welch, D. R., Vaidya, K. S., Hurst, D. R., Silveira, A. C., Zang, X. A., Bari, R., Silveira, A., Szmulewitz, R., Taylor, J., Rinker-Schaffer, C., Shim, H., Plass, C., Lindsey, J. C., Clifford, S. C., Holdenrieder, S., Steinle, A., Salih, H., Brown, D. A., Breit, S. N., Bauskin, A. R., Mousses, S., Lung, M. L., Alix-Panabieres, C., Pantel, K., Djuzenova, C. S., Dalmay, T., Ahlquist, T., Lothe, R. A., Bhat, K., Setaluri, V., Rutka, J. T., Salhia, B., Cockell, K. A., Radich, J. P., Yamagishi, S.-I., Bignami, M., Verma, M., Kumar, D., Brenner, C., Zhang, Y.-W., Jamieson, D., Chi, Y.-H., Jeang, K.-T., Roninson, I., Dragani, T., Sobolev, A. S., Powers, M. V., Workmann, P., Evans, M. F., Cooper, K., Kausch, I., Doehn, C., Janz, S., Huang, C.-L., Toland, A. E., Osinaga, E., Kaye, F., Lemos, M. C., Thakker, R. V., Teh, B. T., Ponder, B. A. J., Mulligan, L. M., Gullo, C., Klein, G., Wu, X., Araten, D. J., Loeb, L. A., Cheadle, J. P., Lipsick, J., Albihn, A., Henriksson, M., Kremens, B., Germing, U., Zangemeister-Wittke, U., Simon, H.-U., Yu, Y. P., Luo, J., and Aman, P.

Published
2020

2. Metallothionein enzymes

Author

Pollard, J. W., Danilkovitch-Miagkova, A., Minaguchi, T., Waite, K. A., Buys, T. P. H., Lam, W. L., Müller-Hermelink, H. K., Ott, G., Robb, V. A., Henske, E. P., Lynge, E., Boyd, N., Geisler, C., Seger, R., De Wolf-Peeters, C., Sagaert, X., Sheng, S., Ribatti, D., Verstovsek, S., Akin, C., Stack, M. S., Kitada, S., Gartenhaus, R., Moretti, F., Frühwald, Michael C., Mooi, W. J., Krausz, T., Kefford, R., Peikert, T., Specks, U., Tueting, T., Pföhler, C., Blask, D. E., Stevens, R. G., Nies, A. T., Gotoh, N., Tsuchida, N., Escriba, P., Singh, V., Hickey, M., Saunders, C., Xiao, G.-H., Testa, J. R., Furtwängler, R., Scholler, N., Carbone, M., Furge, K., Woude, G. F. V., Roland, W. C., Muschel, R., Hunter, K., Welch, D. R., Vaidya, K. S., Hurst, D. R., Silveira, A. C., Zang, X. A., Bari, R., Silveira, A., Szmulewitz, R., Taylor, J., Rinker-Schaffer, C., Shim, H., Plass, C., Lindsey, J. C., Clifford, S. C., Holdenrieder, S., Steinle, A., Salih, H., Brown, D. A., Breit, S. N., Bauskin, A. R., Mousses, S., Lung, M. L., Alix-Panabieres, C., Pantel, K., Djuzenova, C. S., Dalmay, T., Ahlquist, T., Lothe, R. A., Bhat, K., Setaluri, V., Rutka, J. T., Salhia, B., Cockell, K. A., Radich, J. P., Yamagishi, S.-I., Bignami, M., Verma, M., Kumar, D., Brenner, C., Zhang, Y.-W., Jamieson, D., Chi, Y.-H., Jeang, K.-T., Roninson, I., Dragani, T., Sobolev, A. S., Powers, M. V., Workmann, P., Evans, M. F., Cooper, K., Kausch, I., Doehn, C., Janz, S., Huang, C.-L., Toland, A. E., Osinaga, E., Kaye, F., Lemos, M. C., Thakker, R. V., Teh, B. T., Ponder, B. A. J., Mulligan, L. M., Gullo, C., Klein, G., Wu, X., Araten, D. J., Loeb, L. A., Cheadle, J. P., Lipsick, J., Albihn, A., Henriksson, M., Kremens, B., Germing, U., Zangemeister-Wittke, U., Simon, H.-U., Yu, Y. P., Luo, J., and Aman, P.

Published
2020

3. Randomised Introduction of 2-CDA as Intensification during Consolidation for Children with High-risk AML--results from Study AML-BFM 2004

Author

Creutzig, U, Dworzak, M, Zimmermann, M, Bourquin, J-P, Gruhn, B, Fleischhack, G, Graf, N, Klingebiel, T, Kremens, B, Lehrnbecher, T, von Neuhoff, C, von Stackelberg, A, Stray, J, Reinhardt, D, University of Zurich, and Creutzig, U

Subjects
10036 Medical Clinic, 610 Medicine & health, 2735 Pediatrics, Perinatology and Child Health
Published
2015
Full Text
View/download PDF

4. In 80 Stunden zum pädiatrischen Dozenten? Evaluation des Peer-teaching an der Universitätskinderklinik Essen

Author

Weber, D, Groes, B, Kremens, B, and Büscher, R

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Fragestellung: Peer-assisted learning ist an den medizinischen Fakultäten in Deutschland weit verbreitet, in der Kinderheilkunde aber eher eine Ausnahme. An der Universitätskinderklinik Essen werden seit 1986 studentische Tutoren in einem zehntägigen Intensivkurs ausgebildet, um im Bl[for full text, please go to the a.m. URL], Jahrestagung der Gesellschaft für Medizinische Ausbildung (GMA)

Published
2011
Full Text
View/download PDF

7. MULTIVARIATE ANALYSIS OF RISK FACTORS IN STAGE IV NEUROBLASTOMA PATIENTS OVER THE AGE OF ONE YEAR TREATED WITH MEGATHERAPY AND STEM CELL TRANSPLANTATION: A REPORT FROM THE EUROPEAN BONE MARROW TRANSPLANTATION SOLID TUMOR REGISTRY

Author

Ladenstein, R., Philip, T., Lasset, C., Hartman, O., Garaventa, A., Pinkerton, R., Michon, J., Pritchard, J., Klingebiel, T., Kremens, B., Pearson, A., and Paolucci, Paolo

Subjects
stage 4 neuroblastoma, MULTIVARIATE ANALYSIS OF RISK FACTORS, myeloablative megatherapy, stem-cell transplantation
Published
1998

8. Role of allogeneic bone marrow transplantation for the treatment of myelodysplastic syndromes in childhood. The European Working Group on Childhood Myelodysplastic Syndrome (EWOG-MDS) and the Austria-Germany-Italy (AGI) Bone Marrow Transplantation Registry

Author

Locatelli F, Zecca M, Niemeyer C, Angelucci E, Arcese G, Bender-Gotze C, Bonetti F, Burdach S, Dini G, Ebell W, Friedrich W, Henrik Hasle, Hermann J, Jacobsen N, Klingebiel T, Kremens B, Mann G, Miniero R, Pession A, Peters C, Paolucci P, Rossetti F, Hj, Schmid, Stary J, and Zimmermann M

Subjects
Male, Treatment Outcome, Adolescent, Child, Preschool, Myelodysplastic Syndromes, Humans, Infant, Transplantation, Homologous, Female, allogeneic bone marrow transplantation, myelodysplastic syndrome, children, Child, Bone Marrow Transplantation
Published
1996

12. To the editor

Author

Hero B, Kremens B, Sudermann T, and Haas Rj

Subjects
Pediatrics, medicine.medical_specialty, business.industry, Neuroblastoma, Pediatrics, Perinatology and Child Health, Rare case, Mesoblastic nephroma, Medicine, Surgery, General Medicine, Presentation (obstetrics), business, medicine.disease
Published
2001
Full Text
View/download PDF

13. Role of allogeneic bone marrow transplantation for the treatment of myelodysplastic syndromes in childhood

Author

Locatelli, F., Marco Zecca, Niemeyer, C., Angelucci, E., Arcese, G., Bender-Gotze, C., Bonetti, F., Burdach, S., Dini, G., Ebell, W., Friedrich, W., Hasle, H., Hermann, J., Jacobsen, N., Klingebiel, T., Kremens, B., Mann, G., Miniere, R., Pession, A., Peters, C., Paolucci, P., Rossetti, F., Schmid, H. J., Stary, J., Suttorp, M., Uderzo, C., T Veer-Korthof, E. Th, Vossen, J., and Zimmermann, M.

16. [NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphoma in children and adolescents. Part 3: An intermediate term analysis of the B-NHL/B-ALL]

Author

Reiter A, Schrappe M, Yakisan E, Sauter S, Ebell W, Zimmermann M, Hartmann W, Kremens B, Kuhn N, and Alexander Claviez

Subjects
Male, Lymphoma, B-Cell, Adolescent, Dose-Response Relationship, Drug, Lymphoma, Non-Hodgkin, Infant, Drug Administration Schedule, Survival Rate, Cause of Death, Child, Preschool, Antineoplastic Combined Chemotherapy Protocols, Leukemia, B-Cell, Humans, Female, Child, Follow-Up Studies, Neoplasm Staging
Abstract

The aims of trial NHL-BFM 90 for patients (pts) suffering from B-cell neoplasms are to prove whether: 1. Treatment for pts with complete resection can be reduced from 3 to 2 therapy courses; 2. Results for pts of stage III with large abdominal tumors can be improved by high dose (HD) chemotherapy; 3. Survival for pts with incomplete initial response can be improved by therapy intensification; 4. Intraventricularly applied CNS chemotherapy can improve the outcome for CNS positive pts. Therapy is stratified into 3 branches. Branch 1: completely resected; branch 2: not resected, extra-abdominal localization only or abdominal localization and LDH500 U/l; branch 3: abdominal localization and LDHor = 500 U/l, and all pts with BM or/and CNS involvement or multifocal bone disease. A 5-day prephase is followed by 2 (R1), 4 (R2), 6 (R3) therapy courses composed of dexamethasone (DEXA), methotrexate (MTX) 5 g/m2/24 h (in branch R1, 500 mg/m2), MTX/Cytarabine (ARA-C)/prednisolone (PRED) i.th., vincristine (not in branch R1), ifosfamide alternating with cyclophosphamide, ARA-C/etoposide (VP16) alternating with doxorubicin. CNS pos. pts receive MTX/ARA-C/PRED applied intraventricularly. Pts with incomplete response after 2 courses receive an intensification (DEXA, Vindesine, HD-ARA-C, VP16, and MTX/ARA-C/PRED i.th.). Pts with viable tumor after the intensified course receive mega-dose chemotherapy with autologous BM rescue (aBMT). From 4/1990 to 12/1992, 228 pts were registered; 212 pts are evaluable for response. The probability of event free survival (pEFS) at 3 years is 89 +/- 2% for the whole group, 97 +/- 3% for pts of branch R1 (n = 32), 99 +/- 1% for patients of branch R2 (n = 87), and 77 +/- 4% for patients of branch R3 (n = 94) (median observation time 21 months). 7 pts of branch R3 died early due to infections. 15 pts failed therapy (one pt each in branch R1, and R2, 13 pts in branch R3). pEFS for pts with stage III abdominal disease and LDHor = 500 U/l is 80 +/- 6 as compared to 53 +/- 8% in the preceding studies (p.02). Of 13 evaluable pts with CNS disease 3 died early of infection, however none suffered from relapse. Only 1 of 22 pts of branch R2 who had residual tumors after 2 therapy courses suffered from progress in contrast to 9 of 33 such pts of branch R3. Only 2 pts had viable tumor after the intensification course CC. They received aBMT, both are in CCR.(ABSTRACT TRUNCATED AT 400 WORDS)

19. Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia : results from a phase III trial

Author

Arndt Borkhardt, Birgitte Lausen, Bernhard Kremens, Christian Thiede, Philipp Schulze, Angelika Eggert, Christina Nowasz, Adriana Balduzzi, Sabina Sufliarska, Olga Aleinikova, Petr Sedlacek, Gudrun Göhring, Gabriele Strauss, Frank Berthold, Günter Henze, Andreas H. Groll, Alexander Claviez, Brigitte Schlegelberger, Jochen Harbott, Ingmar Glauche, Hans Kreipe, Ute Groß-Wieltsch, Martin Schrappe, Josephine T. Tauer, Manuela Krumbholz, Eveline S. J. M. de Bont, Christoph Klein, Nils von Neuhoff, Markus Metzler, Andreas E. Kulozik, Karl Walter Sykora, Meinolf Suttorp, Suttorp, M, Schulze, P, Glauche, I, Göhring, G, Von Neuhoff, N, Metzler, M, Sedlacek, P, De Bont, E, Balduzzi, A, Lausen, B, Aleinikova, O, Sufliarska, S, Henze, G, Strauss, G, Eggert, A, Kremens, B, Groll, A, Berthold, F, Klein, C, Groß-Wieltsch, U, Sykora, K, Borkhardt, A, Kulozik, A, Schrappe, M, Nowasz, C, Krumbholz, M, Tauer, J, Claviez, A, Harbott, J, Kreipe, H, Schlegelberger, B, and Thiede, C

Subjects
Male, Cancer Research, medicine.medical_specialty, Adolescent, Medizin, Antineoplastic Agents, Blastic Phase, 03 medical and health sciences, 0302 clinical medicine, Bone Marrow, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, hemic and lymphatic diseases, Internal medicine, medicine, Humans, Treatment Failure, Child, Protein Kinase Inhibitors, Survival rate, Neoplasm Staging, business.industry, Infant, Imatinib, Hematology, Prognosis, medicine.disease, Combined Modality Therapy, Transplantation, Clinical trial, Leukemia, Treatment Outcome, Imatinib mesylate, Oncology, Child, Preschool, 030220 oncology & carcinogenesis, Disease Progression, Imatinib Mesylate, Female, Neoplasm Grading, business, Complete Hematologic Response, Biomarkers, 030215 immunology, medicine.drug
Abstract

A total of 156 patients (age range 1.3-18.0 years, median 13.2 years; 91 (58.3%) male) with newly diagnosed CML (N = 146 chronic phase (CML-CP), N = 3 accelerated phase (CML-AP), N = 7 blastic phase (CML-BP)) received imatinib up-front (300, 400, 500 mg/m 2 , respectively) within a prospective phase III trial. Therapy response, progression-free survival, causes of treatment failure, and side effects were analyzed in 148 children and adolescents with complete data. Event-free survival rate by 18 months for patients in CML-CP (median follow-up time 25 months, range: 1-120) was 97% (95% CI, 94.2-99.9%). According to the 2006 ELN-criteria complete hematologic response by month 3, complete cytogenetic response (CCyR) by month 12, and major molecular response (MMR) by month 18 were achieved in 98, 63, and 59% of the patients, respectively. By month 36, 86% of the patients achieved CCyR and 74% achieved MMR. Thirty-eight patients (27%) experienced imatinib failure because of unsatisfactory response or intolerance (N = 9). In all, 28/148 patients (19%) underwent stem cell transplantation (SCT). In the SCT sub-cohort 2/23 patients diagnosed in CML-CP, 0/1 in CML-AP, and 2/4 in CML-BP, respectively, died of relapse (N = 3) or SCT-related complications (N = 2). This large pediatric trial extends and confirms data from smaller series that first-line imatinib in children is highly effective.

Published
2018

20. Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia

Author

Paul Veys, Claudia Rossig, Martina Ahlmann, Persis Amrolia, S Saiagh, Ettore Biagi, G Wright, Rachael Hough, Martin Pule, Allan Hackshaw, Bernhard Kremens, N Goulden, Martin Sauer, Kim Champion, Paul Smith, Michelle Cummins, Sara Ghorashian, Thomas A. Roberts, B Dreno, Laura Clifton-Hadley, Bilyana Popova, Raphael Rousseau, Sareetha Kailayangiri, Z Sattar, Bianca Altvater, Rossig, C, Pule, M, Altvater, B, Saiagh, S, Wright, G, Ghorashian, S, Clifton Hadley, L, Champion, K, Sattar, Z, Popova, B, Hackshaw, A, Smith, P, Roberts, T, Biagi, E, Dreno, B, Rousseau, R, Kailayangiri, S, Ahlmann, M, Hough, R, Kremens, B, Sauer, M, Veys, P, Goulden, N, Cummins, M, and Amrolia, P

Subjects
Male, 0301 basic medicine, Herpesvirus 4, Human, medicine.medical_specialty, Cancer Research, medicine.medical_treatment, Antigens, CD19, Receptors, Antigen, T-Cell, Medizin, Immunotherapy, Adoptive, 03 medical and health sciences, 0302 clinical medicine, Recurrence, Internal medicine, medicine, Humans, Child, Hematology, Chimera, business.industry, Vaccination, Immunotherapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma, medicine.disease, Chimeric antigen receptor, Leukemia, CTL, Cytokine release syndrome, 030104 developmental biology, Graft-versus-host disease, Anesthesiology and Pain Medicine, Oncology, Child, Preschool, 030220 oncology & carcinogenesis, Immunology, Female, business, T-Lymphocytes, Cytotoxic
Abstract

Trials with second generation CD19 chimeric antigen receptors (CAR) T-cells report unprecedented responses but are associated with risk of cytokine release syndrome (CRS). Instead, we studied the use of donor Epstein–Barr virus-specific T-cells (EBV CTL) transduced with a first generation CD19CAR, relying on the endogenous T-cell receptor for proliferation. We conducted a multi-center phase I/II study of donor CD19CAR transduced EBV CTL in pediatric acute lymphoblastic leukaemia (ALL). Patients were eligible pre-emptively if they developed molecular relapse (>5 × 10-4) post first stem cell transplant (SCT), or prophylactically post second SCT. An initial cohort showed poor expansion/persistence. We therefore investigated EBV-directed vaccination to enhance expansion/persistence. Eleven patients were treated. No CRS, neurotoxicity or graft versus host disease (GVHD) was observed. At 1 month, 5 patients were in CR (4 continuing, 1 de novo), 1 PR, 3 had stable disease and 3 no response. At a median follow-up of 12 months, 10 of 11 have relapsed, 2 are alive with disease and 1 alive in CR 3 years. Although CD19CAR CTL expansion was poor, persistence was enhanced by vaccination. Median persistence was 0 (range: 0–28) days without vaccination compared to 56 (range: 0–221) days with vaccination (P=0.06). This study demonstrates the feasibility of multi-center studies of CAR T cell therapy and the potential for enhancing persistence with vaccination.Leukemia advance online publication, 10 March 2017; doi:10.1038/leu.2017.39

Published
2017

21. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000

Author

Maria Grazia Valsecchi, Valentino Conter, Claudia Rossig, Richard Ratei, Martin Schrappe, Giuseppe Basso, Georg Mann, Jochen Harbott, Anja Möricke, Franco Locatelli, Martin Stanulla, Maurizio Aricò, Bernhard Kremens, Felix Niggli, Elena Barisone, Rita Beier, Jeanette Greiner, Roberta Caruso, Martin Zimmermann, Luca Lo Nigro, Rosanna Parasole, Andreas E. Kulozik, Andrea Biondi, Giovanni Cazzaniga, Claus R. Bartram, Arend von Stackelberg, Daniela Silvestri, Andishe Attarbaschi, Möricke, A, Zimmermann, M, Valsecchi, M, Stanulla, M, Biondi, A, Mann, G, Locatelli, F, Cazzaniga, G, Niggli, F, Aricò, M, Bartram, C, Attarbaschi, A, Silvestri, D, Beier, R, Basso, G, Ratei, R, Kulozik, A, Lo Nigro, L, Kremens, B, Greiner, J, Parasole, R, Harbott, J, Caruso, R, von Stackelberg, A, Barisone, E, Rössig, C, Conter, V, Schrappe, M, and University of Zurich

Subjects
Male, 1303 Biochemistry, Neoplasm, Residual, medicine.medical_treatment, 2720 Hematology, Medizin, Hematopoietic stem cell transplantation, Kaplan-Meier Estimate, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Biochemistry, Gastroenterology, Dexamethasone, law.invention, 1307 Cell Biology, 0302 clinical medicine, Randomized controlled trial, Prednisone, law, Antineoplastic Combined Chemotherapy Protocols, Cumulative incidence, Child, Mortality rate, Remission Induction, Hematopoietic Stem Cell Transplantation, Hematology, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Combined Modality Therapy, Treatment Outcome, Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, 030220 oncology & carcinogenesis, Child, Preschool, Female, dexamethasone, acute lymphoblastic leukemia, children, medicine.drug, medicine.medical_specialty, Adolescent, Immunology, 610 Medicine & health, Disease-Free Survival, 03 medical and health sciences, Internal medicine, Dexamethasone, prednisone, pediatric ALL, medicine, Potency, Humans, Proportional Hazards Models, 2403 Immunology, business.industry, Infant, Cell Biology, Surgery, Methotrexate, 10036 Medical Clinic, Cranial Irradiation, business, ALL, 030215 immunology
Abstract

Induction therapy for childhood acute lymphoblastic leukemia (ALL) traditionally includes prednisone; yet, dexamethasone may have higher antileukemic potency, leading to fewer relapses and improved survival. After a 7-day prednisone prephase, 3720 patients enrolled on trial Associazione Italiana di Ematologia e Oncologia Pediatrica and Berlin-Frankfurt-Munster (AIEOP-BFM) ALL 2000 were randomly selected to receive either dexamethasone (10 mg/m(2) per day) or prednisone (60 mg/m(2) per day) for 3 weeks plus tapering in induction. The 5-year cumulative incidence of relapse (± standard error) was 10.8 ± 0.7% in the dexamethasone and 15.6 ± 0.8% in the prednisone group (P < .0001), showing the largest effect on extramedullary relapses. The benefit of dexamethasone was partially counterbalanced by a significantly higher induction-related death rate (2.5% vs 0.9%, P = .00013), resulting in 5-year event-free survival rates of 83.9 ± 0.9% for dexamethasone and 80.8 ± 0.9% for prednisone (P = .024). No difference was seen in 5-year overall survival (OS) in the total cohort (dexamethasone, 90.3 ± 0.7%; prednisone, 90.5 ± 0.7%). Retrospective analyses of predefined subgroups revealed a significant survival benefit from dexamethasone only for patients with T-cell ALL and good response to the prednisone prephase (prednisone good-response [PGR]) (dexamethasone, 91.4 ± 2.4%; prednisone, 82.6 ± 3.2%; P = .036). In patients with precursor B-cell ALL and PGR, survival after relapse was found to be significantly worse if patients were previously assigned to the dexamethasone arm. We conclude that, for patients with PGR in the large subgroup of precursor B-cell ALL, dexamethasone especially reduced the incidence of better salvageable relapses, resulting in inferior survival after relapse. This explains the lack of benefit from dexamethasone in overall survival that we observed in the total cohort except in the subset of T-cell ALL patients with PGR. This trial was registered at www.clinicaltrials.gov (BFM: NCT00430118, AIEOP: NCT00613457).

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results